Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($1.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08), Morningstar.com reports. Ascendis Pharma A/S had a negative return on equity of 34.64% and a negative net margin of 901.89%. The firm had revenue of $3.61 million for the quarter, compared to analyst estimates of $0.68 million.

NASDAQ ASND traded down $0.74 on Thursday, hitting $110.96. 4,013 shares of the company were exchanged, compared to its average volume of 217,331. The company has a market cap of $4.83 billion, a PE ratio of -29.67 and a beta of 0.62. Ascendis Pharma A/S has a 12 month low of $53.21 and a 12 month high of $133.96. The stock has a fifty day moving average of $114.52 and a 200-day moving average of $112.82. The company has a current ratio of 22.32, a quick ratio of 22.32 and a debt-to-equity ratio of 0.02.

Hedge funds and other institutional investors have recently modified their holdings of the stock. NumerixS Investment Technologies Inc bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $94,000. Private Ocean LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $113,000. Tobam bought a new position in shares of Ascendis Pharma A/S during the second quarter valued at about $157,000. First Trust Advisors LP bought a new position in shares of Ascendis Pharma A/S during the second quarter valued at about $215,000. Finally, Telemus Capital LLC bought a new position in shares of Ascendis Pharma A/S during the first quarter valued at about $235,000.



ASND has been the subject of several recent analyst reports. Canaccord Genuity increased their price objective on shares of Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a research report on Friday, May 31st. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research report on Thursday. BidaskClub cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Monday, June 24th. Wedbush reiterated a “buy” rating and set a $223.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, June 28th. Finally, Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $138.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Trade Deficit

Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.